Athenex Appoints Teresa Bair, Esq. as Executive Officer and General Counsel
June 23 2020 - 07:00AM
Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced the promotion of Teresa Bair, Esq. to Executive
Officer as General Counsel and Senior Vice President,
Administration. She will report to Athenex’s Chief Executive
Officer.
Ms. Bair, who has more than 23 years of private and in-house
legal experience, advances from the position of Senior Vice
President, Legal Affairs and Administration. Since joining
Athenex in 2015, she has held various roles with increasing
responsibility. As General Counsel, she will continue
overseeing all legal matters of the Company worldwide and serving
as Corporate Secretary to the Board of Directors. As Senior
Vice President, Administration, Ms. Bair will lead administration
and government relations for U.S. operations and work closely with
the Company’s senior management team across the globe.
“Teresa’s valuable legal counsel and unmatched corporate
knowledge and experience have made her an institutional asset to
Athenex,” stated Dr. Johnson Lau, Athenex’s Chief Executive Officer
and Chairman of the Board of Directors. “She is involved in
every aspect of the business and remains fully dedicated to the
achievement of our corporate objectives. Teresa will also
continue to play a critical role in advising the Board and
leadership team on legal and corporate governance matters. We are
delighted to expand her role to that of an Executive Officer and we
are confident she will continue to be a strong and prominent leader
within Athenex.”
Ms. Bair added, “All of us at Athenex are driven by the prospect
of creating new paradigms in the treatment of cancer. I am
excited to take on a new role as Executive Officer and General
Counsel as we execute on our mission of bringing innovative cancer
treatments to the market and improving health outcomes
globally.”
Prior to joining Athenex, Ms. Bair was a partner at Harris Beach
PLLC, a nationally recognized law firm, where she successfully
represented and advised business clients, including Fortune 500
companies, on complex and diverse matters. She serves on the
Boards of Directors of BirchBioMed Inc., the University at Buffalo
Law Alumni Association, and the Western New York Women’s
Foundation, as well as the Advisory Boards of Varia Ventures and
the Buffalo Institute for Genomics & Data Analytics. She
received her law degree (JD) from University at Buffalo School of
Law, and a Bachelor of Science in Business Administration from
Bowling Green State University.
About Athenex, Inc.Founded in 2003, Athenex,
Inc. is a global clinical stage biopharmaceutical company dedicated
to becoming a leader in the discovery, development and
commercialization of next generation drugs for the treatment of
cancer. Athenex is organized around three platforms, including an
Oncology Innovation Platform, a Commercial Platform and a Global
Supply Chain Platform. The Company’s current clinical pipeline is
derived from four different platform technologies: (1) Orascovery,
based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3)
T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine
deprivation therapy. Athenex’s employees worldwide are dedicated to
improving the lives of cancer patients by creating more active and
tolerable treatments. Athenex has offices in Buffalo and
Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago,
Illinois; Hong Kong; Taipei, Taiwan; multiple locations in
Chongqing, China; Manchester, UK; Guatemala City, Guatemala and
Buenos Aires, Argentina. For more information, please visit
www.athenex.com.
CONTACTSAthenex, Inc.: Randoll Sze Chief
Financial Officer Email: RandollSze@athenex.com
Jacqueline Li Corporate Development and Investor Relations
Email: JacquelineLi@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2023 to Mar 2024